Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:07 PM
Ignite Modification Date:
2025-12-24 @ 3:07 PM
NCT ID:
NCT06999759
Eligibility Criteria:
Inclusion Criteria:
* 5-10 years old (The scale used is between this age group, these children should be willing to draw and should be suitable for their developmental periods)
* Inpatients with cancer,
* Those receiving the second and subsequent courses of chemotherapy,
* Previous chemotherapy experience,
* Those receiving chemotherapy drugs, the duration of chemotherapy lasting an average of 1 to 6 hours
* Those taking chemotherapy drugs with minimal, low and moderate severity of nausea and vomiting,
* Children whose parents agreed to participate in the study were included in the study.
Exclusion Criteria:
* Those in the last stage of cancer (experiencing the side effects of treatment intensively during hospitalisation due to the disease and symptoms causing complications)
* Those receiving oral chemotherapy,
* Those who experience intense side effects of chemotherapy (febrile neutropenia, bleeding, allergic reactions),
* People with mental problems (depression, anxiety disorders, disruptive behaviour disorders, neurodevelopmental disorders),
* People on antidepressant medication,
* Those who have a physical disability (e.g. amputation, lack/inability to use arms, hands and fingers, visual or hearing impairment, etc.) to paint during chemotherapy, and
* Children taking medicines with high severity of nausea and vomiting were not included in the study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
5 Years
Maximum Age:
10 Years
Study:
NCT06999759
Study Brief:
Protocol Section:
NCT06999759